Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1576219 | 0.92 | GPR119 (0.60) | GPR119KDM4ESCN9APKM | |
| SCHEMBL1575885 | 0.91 | GPR119 (0.61) | GPR119KDM4ESCN9APKM | |
| SCHEMBL1576096 | 0.88 | GPR119 (0.64) | GPR119ALDH1A1SCN9A | |
| SCHEMBL1575798 | 0.88 | GPR119 (0.57) | GPR119KDM4ESCN9APKM | |
| SCHEMBL1575179 | 0.88 | GPR119 (0.66) | GPR119KDM4EMEN1ALDH1A1HPGD | |
| SCHEMBL1575345 | 0.87 | GPR119 (0.65) | GPR119KDM4ESCN9APKM | |
| SCHEMBL1575233 | 0.84 | GPR119 (0.62) | GPR119SCN9A | |
| SCHEMBL14621810 | 0.84 | GPR119 (0.61) | GPR119SCN9A | |
| SCHEMBL1575373 | 0.82 | GPR119 (0.57) | GPR119SCN9A | |
| SCHEMBL1576224 | 0.82 | GPR119 (0.59) | GPR119SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172358-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172358-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172358-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| EP-2308840-A1 | GPCR agonists | Prosidion Limited (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-20100063081-A1 | CPCR Agonists | PROSIDION LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063081-A1 | CPCR Agonists | PROSIDION LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063081-A1 | CPCR Agonists | PROSIDION LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172358-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885KDM4E 3925/4885MEN1 3467/4885 |
| US-20100063081-A1 | CPCR Agonists | GPR119, GCGR, GLP1R | GPR119 1/4885KDM4E 3476/4885MEN1 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.